Comments
Loading...

Apellis Pharmaceuticals

APLSNASDAQ
Logo brought to you by Benzinga Data
$35.63
0.10.28%
At Close: -
$35.63
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$141.00
Lowest Price Target1
$41.00
Consensus Price Target1
$74.11

Apellis Pharmaceuticals (NASDAQ:APLS) Stock, Analyst Ratings, Price Targets, Forecasts

Apellis Pharmaceuticals Inc has a consensus price target of $74.11 based on the ratings of 19 analysts. The high is $141 issued by Goldman Sachs on April 14, 2023. The low is $41 issued by Wedbush on August 9, 2024. The 3 most-recent analyst ratings were released by JP Morgan, JP Morgan, and UBS on September 13, 2024, August 13, 2024, and August 9, 2024, respectively. With an average price target of $68 between JP Morgan, JP Morgan, and UBS, there's an implied 90.85% upside for Apellis Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
May
1
Jun
2
Jul
2
1
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JP Morgan
UBS
Wedbush
Goldman Sachs
Baird

1calculated from analyst ratings

Analyst Ratings for Apellis Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Apellis Pharmaceuticals (APLS) stock?

A

The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by JP Morgan on September 13, 2024. The analyst firm set a price target for $57.00 expecting APLS to rise to within 12 months (a possible 59.98% upside). 59 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?

A

The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by JP Morgan, and Apellis Pharmaceuticals maintained their overweight rating.

Q

When was the last upgrade for Apellis Pharmaceuticals (APLS)?

A

The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.

Q

When was the last downgrade for Apellis Pharmaceuticals (APLS)?

A

The last downgrade for Apellis Pharmaceuticals Inc happened on December 14, 2023 when Wells Fargo changed their price target from $67 to $54 for Apellis Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on September 13, 2024 so you should expect the next rating to be made available sometime around September 13, 2025.

Q

Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?

A

While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $64.00 to $57.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $35.63, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch